Equity Research Medical Instruments & Supplies

Should You Buy Yubo International Biotech Limited Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Yubo International Biotech Limited (YBGJ) scores 4.5/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.01, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 0 CirclFi valuation models project upside for Yubo International Biotech Limited (YBGJ) at $0.01 — the models are evenly split, with a Quality Score of 4.5/10 and Value-Trap risk of 42/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 4.5/10 — Weak — below-average fundamentals
  • Value Trap Risk: 42/100 — Elevated — exercise caution
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

4.5 /10

Weak — below-average fundamentals

Value Trap Risk

42 /100
Elevated

Elevated — exercise caution

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for Yubo International Biotech Limited (YBGJ) in 2026?

What Is the Bull Case vs the Bear Case for Yubo International Biotech Limited (YBGJ)?

Bull case versus bear case for Yubo International Biotech Limited (YBGJ) at $0.01, derived from 0 active CirclFi valuation models on 2026-08-27.
Bull case Bear case
No active model projects meaningful upside for YBGJ at $0.01. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for YBGJ. The Value Trap score of 42/100 still argues for some caution.

How Does YBGJ Compare to Its Medical Instruments & Supplies Peers?

DXR Daxor Corporation
4.6
RGNT Regentis Biomaterial
4.3
PLSE Pulse Biosciences, I
5.3
UEEC United Health Produc
4.1
ZTEK Zentek Ltd.
5.4
TUTH Standard Dental Labs
3.2
COO The Cooper Companies
8.5
SOLV Solventum Corporatio
7.2

Valuation data pages: DXR · RGNT · PLSE · UEEC · ZTEK · TUTH · COO · SOLV · MLSS · ISRG · RMD

See full Medical Instruments & Supplies rankings →

Which Other Stocks Score Like YBGJ on Quality?

Closest companies to YBGJ’s Quality of Company score of 4.5/10, across all industries.

Why Do CirclFi’s 0 Models Disagree on YBGJ?

What Are the Biggest Risks of Buying YBGJ Stock?

Weak Fundamentals

QOC 4.5/10 signals below-average quality.

Value Trap Warning

VT score 42/100 — apparent discount may mask decay.

Macro/Sector Risk

Medical Instruments & Supplies headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View YBGJ Data Page →

So Is Yubo International Biotech Limited (YBGJ) Worth Buying in 2026?

Yubo International Biotech Limited currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. Yubo International Biotech Limited's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About YBGJ Stock?

Should I buy YBGJ stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for YBGJ at $0.01. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Yubo International Biotech Limited?

Key risks include: an elevated Value Trap score of 42/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.5/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.

How does YBGJ compare to its competitors?

Among Medical Instruments & Supplies peers, YBGJ holds a Quality Score of 4.5/10. Comparable companies include DXR (QOC 4.6), RGNT (QOC 4.3), PLSE (QOC 5.3). The relative ranking helps investors identify whether YBGJ offers better fundamental quality than alternatives in the same sector.

Is YBGJ a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. YBGJ's Quality Score of 4.5/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy YBGJ at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for YBGJ.

View YBGJ Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →